2 510(k) Summary

Submitter: VeriSci Corporation
106 Anderson Street
Raritan, New Jersey 08869-1514
Telephone: (908) 725-5213
Fax: (908) 725-4617

Contact Person: George Hu, Ph.D.
CEO

Trade Name: Neucodia

Classification Name: Stimulator, Photic, Evoked Response
Regulation Number: 882.1890
Classification Product Code: GWE
Regulatory Class: II

2.1 Identification of Legally Marketed Predicate Devices

The Neucodia system is substantially equivalent to Roland Consult's RETI-Port-Scan (K023525) and LACE Elettronica's GLAID Ocular Electrophysiology Device (K043367). The Neucodia device features are substantially equivalent to the predicate devices with respect to the device's general design concept, operational procedure, data processing methodology, data acquisition conditions, and indications for use. All the devices are electrophysiological (EEG) test systems that consist of electrical hardware and software to produce visual stimuli, EEG signal recording and processing for extraction of visual evoked potentials (VEPs). All the devices are intended to be used by trained medical professionals for the study of central visual functions.

2.2 Device Description

Visual stimuli are presented to the patient on the stimulus monitor. Visual evoked potentials are extracted from EEG epochs recorded via medical-rated EEG electrodes (not included in the device) attached to the scalp of the patient. Once the recording is complete, the digitized EEG data are processed by the software algorithm for noise filtering, artifact rejection, frequency and time domain analysis. The results are displayed on the user's monitor: EEG epochs, spectrum, Fourier components, and statistical measures (e.g., means, deviations, and signal to noise ratio).

2.3 Indications for Use

The Neucodia system is an electrophysiological device that generates photic stimuli, and records, processes and analyzes the resultant visual evoked potential (VEP) signals for the study of central visual functions.
### 2.4 Substantial Equivalence

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Predicate Devices</th>
<th>Submission Device</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roland Consult RETI-Port-Scan (K023525)</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>LACE Elettronica GLAID Ocular (K043367)</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>VeriSci Neucodia</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Indications for use
Electrophysiological device that measures and processes electroencephalographic signals elicited by visual stimuli presented on electronic display for the study of visual function

#### Intended users
Vision researchers, neurologists, eye-care professionals, and trained medical technicians

#### Intended population
Normal observers, individuals at-risk for visual pathway dysfunction or with confirmed ophthalmic disorders

#### Site of use
Hospital, clinics, physicians' offices, and research laboratories

#### Data collected
EEG signals

#### Stimuli
Patterns on screen displayed in periodical functions

#### Data processing
Frequency domain and time domain analysis, statistical analysis

#### Hardware for signal amplification and AD converting
(Filter bandwidth, sampling rate, AD converting accuracy, Gain, CMRR, input impedance, input/output voltage range)

Conforms ISCEV standard

### 2.5 Performance and Validation

**Software: Verification and validation**

Safety test: UL 60601-1, IEC 60601-2-26, EN60601-1-2, ISO15004-2

System: Bench testing for power supply requirement, amplifier gain and CMRR

Clinical testing:

VEP multi-variable statistics and signal to noise ratio were measured to produce system repeatability and reproducibility. 10 repeated sequential tests were performed on each subject to obtain repeatability performance data. In addition, each subject had three visits for the same repeated tests using different devices and with different operators and reapplication of electrodes to obtain reproducibility performance data. The clinical test results are described in Section 4.2.18, User's Manual and Section 5.2.3, Device Description.
Dear Dr. Hu:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health’s (CDRH’s) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, “Misbranding by reference to premarket notification” (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please contact the CDRH/Office of Surveillance and Biometrics/Division of Postmarket Surveillance at 240-276-3464. For more information regarding the reporting of adverse events, please go to http://www.fda.gov/cdrh/mdr/.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Mark N. Melkerson
Director
Division of Surgical, Orthopedic, and Restorative Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure
1 Indications for Use

Device Name: NEUCODIA

Indications for Use:
The Neucodia system is an electrophysiological device that generates photic stimuli, and records, processes and analyzes the resultant visual evoked potential (VEP) signals for the study of central visual functions.

Prescription Use X AND/OR Over-The-Counter Use _____
(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

[Signature]

Division of Surgical Orthopedic, and Restorative Devices

510(k) Number K081591